Sep 01, 2024
Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024
Aug 28, 2024
Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024
Aug 28, 2024
Innovent Announces 2024 Interim Results and Business Updates
Aug 21, 2024
China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China
Aug 01, 2024
Innovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of China
Jul 25, 2024
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
Jul 07, 2024
Innovent Launches Environmental, Social and Governance (ESG) Website to Advance Sustainability and Corporate Responsibility
Jul 05, 2024
Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy
Jul 01, 2024
Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Jun 27, 2024
Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline
Jun 24, 2024
Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024
Jun 18, 2024
Innovent Reports Oncology Pipeline Updates at Investor Meeting
Jun 13, 2024
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
Jun 12, 2024
Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
Jun 11, 2024
Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions
Jun 02, 2024
Innovent Announces Taletrectinib ROS1 Inhibitor Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
Jun 02, 2024
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer
Jun 02, 2024
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting
Jun 01, 2024
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
Jun 01, 2024
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer